Vimseltinib is a small molecule commercialized by Ono Pharmaceutical, with a leading Pre-Registration program in Tenosynovial Giant Cell Tumor.

Fibromun is a fusion protein commercialized by Philogen, with a leading Phase III program in Soft Tissue Sarcoma.